|
Oct 7
|
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
|
|
Sep 30
|
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
|
|
Aug 28
|
Biora Therapeutics Announces Positive Nasdaq Listing Decision
|
|
Aug 26
|
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
|
Jun 11
|
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
|
|
May 20
|
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
|
|
May 16
|
BIOR: BT-600 Data in June
|
|
May 16
|
Biora Therapeutics Inc (BIOR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...
|
|
May 15
|
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
May 7
|
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
|
|
May 6
|
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
|
|
Apr 30
|
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
|
|
Apr 8
|
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
|
|
Apr 4
|
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
|
|
Apr 3
|
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Apr 1
|
Biora Therapeutics Full Year 2023 Earnings: Beats Expectations
|
|
Apr 1
|
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Mar 27
|
BIOR: Negotiations Accelerating
|
|
Mar 27
|
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
Q4 2023 Biora Therapeutics Inc Earnings Call
|